- |||||||||| Undisclosed CDK2 degrader / Plexium
Discovery of potent and selective bivalent CDK2 degraders that demonstrate activity in CCNE1amp driven tumors (Section 27) - Mar 5, 2024 - Abstract #AACR2024AACR_5463;
Potent and selective CDK2 bivalent degraders were exploited as tools for studying the sensitivity of CCNE1 amplified tumor models to CDK2 degradation and dependence on E3 ligase. This proof-of concept study supports Plexium's current approach of discovering novel CDK2 molecular glue degraders for the treatment of CDK4/6 inhibitor-na
|
